Real-world use and survival outcomes of sacituzumab govitecan in metastatic triple-negative breast cancer and hormone receptor-positive/HER2-negative metastatic breast cancer
The study highlights SG's clinical relevance and the challenge of translating trial efficacy into real-world outcomes, reinforcing the need for further investigation of tolerability in broader populations.
Authors
- Mahmoud Zureik (ORCID: https://orcid.org/0000-0002-8393-4217)
- Stéphane Vignot (ORCID: https://orcid.org/0000-0002-1292-6631)
- David Desplas (ORCID: https://orcid.org/0000-0003-1151-3867)
- Aya Elhusseiny Shaaban
- Hugo Jourdain
- Nadia Haddy
Institutions
- Conservatoire National des Arts et Métiers (FR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Université Paris-Saclay (FR)
- Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail (FR)
- Institut Jean Godinot (FR)
- Université de Reims Champagne-Ardenne (FR)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2026-02-05
- DOI
- https://doi.org/10.1038/s41416-026-03346-9
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00